
Opinion|Videos|January 11, 2024
Key Takeaways from SABCS 2023 in HER2+ Breast Cancer
Following their review of clinical trial data presented at SABCS 2023, the Oncology Brothers discuss their key takeaways on recent updates in HER2+ breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5









































